1 240

Cited 0 times in

Radioembolization With Yttrium-90 Resin Microspheres in Hepatocellular Carcinoma: A Multicenter Prospective Study

 Kim, Do Young ; Park, Beom Jin ; Joo, Young Eun ; Kim, Jae Kyu ; Heo, Jeong ; Kim, Chang Won ; Chung, Jin Wook ; Yoon, Jung-Hwan ; Lee, Kwang Hun MD†† ; Gwon, Dong Il ; Lee, Han Chu ; Chun, Ho Jong ; Choi, Jong Young ; Choe, Jae-Gol ; Uhm, Sun-Ho ; Cho, Kyu Ran ; Cho, Sung Bum ; Han, Kwang-Hyub ; Kim, Yun Hwan 
 American Journal of Clinical Oncology, Vol.38(5) : 495~501, 2015 
Journal Title
 American Journal of Clinical Oncology 
Issue Date
OBJECTIVES: The aim of this prospective study was to reveal the efficacy and safety of Yttrium-90 (Y) radioembolization in Korean patients with hepatocellular carcinoma (HCC). METHODS: A total of 40 HCC patients were prospectively recruited from 7 centers. The response to treatment was assessed on the basis of the modified Response Evaluation Criteria in Solid Tumors criteria. The time to progression and overall survival were also evaluated, and the assessment of safety was done according to National Cancer Institute Common Terminology Criteria, Version 3.0. RESULTS: Forty-two treatments of Y radioembolization were carried out. Median follow-up was 29 months. At 3 months, the complete response, partial response (PR), and stable disease were seen in 4 (10.0%), 19 (47.5%), and 15 (37.5%) patients, respectively. The response rate was 57.5% (23/40), and disease control rate was 95% (38/40) at 3 months. The response rate at 6 months was 63.9% (23/36), and disease control rate was 83.3% (30/36). The median time to progression was 18 months. During follow-up, 10 HCC-related deaths occurred and the 3-year survival rate was 75%. In 19 patients with Barcelona Clinic Liver Cancer-B stage, the 3-year survival rate was 50%. The tumor number (>5) was the only significant predictor associated with survival. The most common adverse event was abdominal pain of mild to moderate degree, and all the complications were manageable. Twenty-six (65%) patients underwent other treatments such as transarterial chemoembolization because of local progression or remnant viable lesion.
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Radiology
1. 연구논문 > 1. College of Medicine > Dept. of Internal Medicine
Yonsei Authors
사서에게 알리기
RIS (EndNote)
XLS (Excel)


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.